Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • COVID-19
    • Safety
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Without My Fellowship Program and ONS, I Would Not Be the Nurse I Am Today
    Nurse empowerment
    Without My Fellowship Program and ONS, I Would Not Be the Nurse I Am Today
    July 15, 2022
    When the Provider Becomes the Patient: What I Learned From COVID-19
    COVID-19
    When the Provider Becomes the Patient: What I Learned From COVID-19
    June 24, 2022
    The Case of the Late Head and Neck Lymphedema
    Clinical practice
    The Case of the Late Head and Neck Lymphedema
    June 20, 2022
    Our Patients Give Us Peace in Unexpected Circumstances
    Oncology nurse pride
    Our Patients Give Us Peace in Unexpected Circumstances
    June 17, 2022
    Behind Our Masks, I See You, I Hear You
    COVID-19
    Behind Our Masks, I See You, I Hear You
    June 10, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    Break Bad News to Patients With This Step-by-Step Guide
    Advanced Practice Nursing (APRN)

    Break Bad News to Patients With This Step-by-Step Guide

    When hearing results from blood work or repeat imaging—regardless of whether they are “good” or “bad”—patients want and deserve to be given information truthfully and objectively. Oncology advanced practice providers are often the bearers of bad news, which can be uncomfortable and stressful. But here’s how you can hold those conversations with finesse, empathy, and respect.

    January 13, 2022
    Oncology Drug Reference Sheet: Amivantamab-Vmjw
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Amivantamab-Vmjw

    After clinical trials demonstrated a 40% overall response rate with 63% of responses lasting six months or more, on May 21, 2021, the U.S. Food and Drug Administration (FDA) approved amivantamab-vmjw (RybrevantTM) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion variants, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

    December 28, 2021

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    Aileen Anglin APRN, ACNP-BC, AOCNP®
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2022 Oncology Nursing Society
     
    Back to Top ▲